Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (GREY:FRTX)

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

GlobeNewswire September 17, 2021

Brickell Biotech to Participate at Upcoming September Conferences

GlobeNewswire September 8, 2021

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

GlobeNewswire September 1, 2021

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

GlobeNewswire September 1, 2021

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

GlobeNewswire August 16, 2021

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2021

Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

GlobeNewswire July 29, 2021

Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter's Option to Purchase Additional Shares

GlobeNewswire July 22, 2021

Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

GlobeNewswire July 19, 2021

Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

GlobeNewswire July 19, 2021

Brickell Biotech to Participate at William Blair's Biotech Focus Conference 2021

GlobeNewswire July 6, 2021

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

GlobeNewswire June 29, 2021

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

GlobeNewswire June 24, 2021

Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

GlobeNewswire June 1, 2021

Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2021

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

GlobeNewswire April 29, 2021

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

GlobeNewswire April 27, 2021

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

GlobeNewswire April 23, 2021

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology's 2021 VMX

GlobeNewswire April 16, 2021

Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 9, 2021